Categories
Archives
Receive Email Updates

-


-
Certified Licensing Professionals, Inc., 2021 Disclaimer
This blog, Patents4Life, does not contain legal advice and is for informational purposes only. Its publication does not create an attorney-client relationship nor is it a solicitation for business. This is the personal blog of Warren Woessner and does not reflect the views of Schwegman Lundberg & Woessner, or any of its attorneys or staff. To the best of his ability, the Author provides current and accurate information at the time of each post, however, readers should check for current information and accuracy.
- About Me

Warren D. Woessner
Pages
Archives
Tag Archives: Warren Woessner
In Search of University Patents
Technology Transfer Tactics, in conjunction with FreePatentsOnline, has created a site (link below) which they state can allow the visitor to view all of a given university’s patents by just clicking on the name of the institution. However, while this … Continue reading
Federal Circuit Throws a Wrench into “Mechanism of Action” Claims
A three-judge panel of the Court of Appeals for the Federal Circuit recently decided Ariad Pharmaceuticals, Inc. et al. v. Eli Lilly & Company, appeal no. 2008-1248 (Fed. Cir. April 3, 2009), involving Blatimore et al. (U.S. Pat. No. 6,410,516). … Continue reading
Kubin Analysis Continued
My last post began a rather selective analysis of In re Kubin, which the Federal Circuit decided on April 3, 2009 (see previous post for citations to this and related decisions). Kubin’s claims to DNA molecules encoding sequences including that … Continue reading
Posted in Obviousness
Tagged biotechnology, Federal Circuit, Goodwin, Hoeksema, Kubin, Lilly vs. UC, patent attorney, patent gap, patents, valiente, Warren Woessner
Leave a comment
Federal Circuit upholds Board In re Kubin – Resurrects O’Farrell Test of “Obvious to Try”
On April 3, 2009, a three judge panel of the Court of Appeals for the Federal Circuit unanimously affirmed the decision that the Board of Patent Appeals had reached in Ex Parte Kubin. The Board’s decision is discussed in the … Continue reading
